SL
Solid Biosciences Inc.
SLDB · NASDAQ
$8.90 +0.34% (+$0.03)
1M -2.73%
Market Cap $876.2M
P/E Ratio -
Div. Yield -
ROE 72.28%
Bulios Fair Price
$5.64
36.6% downside
Current Price
$8.9
Undervalued Fair Value Overvalued
According to Bulios Fair Price, SLDB is currently overvalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Piotroski F-Score Weak
2/9Valuation
79 /100
Cheap P/B 2.34x
EV/FFO N/A
P/E N/A
Growth
0 /100
Declining Book val. growth 5.26%
FCF growth N/A
EPS growth N/A
Profitability
-
N/A Op. margin N/A
Gross margin N/A
FCF margin N/A
Quality
0 /100
Poor ROA 49.24%
ROIC 53.81%
Asset turnover 0.00x
Debt
100 /100
Low Current ratio 13.82x
Debt/Equity 0.05x
Debt/Assets N/A
Stability
44 /100
Moderate Profitable years 0
Beta 2.44x
EPS volatility 9.49%
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about SLDB
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Alexander G. Cumbo
Employees
121
Headquarters
Charlestown
Upcoming events
02 NOV
Earnings
Upcoming earnings report